Showing 20 of 112 recruiting trials for “Adult hepatocellular carcinoma”
Needle-based Percutaneous Ablation of Liver Tumors.
Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation
👨⚕️ Francesco Vasuri, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Oct 2024View details ↗
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
RecruitingNCT06602011 ↗
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
RecruitingNCT06569498 ↗
Neoadjuvant Triple Therapy for Resectable HCC
RecruitingNCT06777628 ↗
Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
👨⚕️ Laura Gramantieri, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Sep 2024View details ↗
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RecruitingNCT07303712 ↗
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Phase 2 Study of WGI-0301 for Advanced HCC
Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
👨⚕️ Eric Roeland, M.D., FAAHPM, FASCO, OHSU Knight Cancer Institute📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06430983 ↗
Recurrent Liver Cancer: Reconceptualization and Reevaluation
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started May 2024View details ↗
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation
👨⚕️ Fabrizio Di Benedetto, University of Modena and Reggio Emilia📍 1 site📅 Started Feb 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →